March 2016- Volume 12, Issue 3

March 2016

In this Issue

Preclinical

Gates Foundation bets big on Moderna’s mRNA technology

Gates Foundation bets big on Moderna’s mRNA technology

Gates Foundation bets big on Moderna’s mRNA technology

Grant will provide support for GLP toxicology studies, preparations for clinical trials and a Phase 1 study

Cornering C. diff.

Cornering C. diff.

Immuron posts positive preclinical results for oral therapeutic IMM-529

A novel approach to depression?

A novel approach to depression?

Rapastinel may sidestep cognitive deficits seen with ketamine

RedHill and Fraunhofer collaborate on cancer drug

RedHill and Fraunhofer collaborate on cancer drug

Novel mechanism may be especially promising for pancreatic cancer patients

Discovery

TSRI researchers develop versatile new way to build molecules

TSRI researchers develop versatile new way to build molecules

Chemists at The Scripps Research Institute (TSRI) have devised a new, widely applicable technique for building potential drug molecules

Flying high in the cloud

Flying high in the cloud

Cloud Pharmaceuticals discovers how to design molecules faster and better

Illumina signs biobank deals with four institutions

Illumina signs biobank deals with four institutions

Prominent role of arrays in company’s overall portfolio recently has focused it more on biobank segment

Enzymes, ion channels and cryo-electron microscopy, oh my!

Enzymes, ion channels and cryo-electron microscopy, oh my!

Recent advances in cryo- electron microscopy are enabling new discoveries at TSRI

Contract Services

COMPASS points east to Japan

COMPASS points east to Japan

EPS Corporation to run clinical studies using BioClinica RBM solution

Bringing contract manufacturing closer

Bringing contract manufacturing closer

Novasep adds specialized drug development technologies for North American customers

TraceLink boosts leadership position

TraceLink boosts leadership position

Track-and-trace network exceeds 200,000 supply chain members

U.K.-based Onyx expands following strong year

U.K.-based Onyx expands following strong year

Second such expansion since last year driven in part by demand for API services

Business & Government Policy

An early acquisition with Affymetrix

An early acquisition with Affymetrix

Thermo Fisher Scientific looks to acquire Affymetrix, with expected deal completion in Q2

Biogen kicks off ALS funding challenge

Biogen kicks off ALS funding challenge

With an initial $5-million donation, goal for Biogen and Target ALS is $20 million more in corporate funding

Sealing the deals

Sealing the deals

Astellas, Bristol-Myers Squibb and Cipla all complete important deals in mid- to late-February

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

For your approval

For your approval

A collection of recent regulatory approvals and actions globally

Patent Docs: What’s in a name? When the chemical structure of an API is wrong

Patent Docs: What’s in a name? When the chemical structure of an API is wrong

Drug regulation and licensing (and the patents that claim active pharmaceutical ingredients) are based on accuracy, including accurate descriptions of the molecule, how it is formulated and (to the extent it is understood) how it works. But what happens when there is an error?

Diagnostics

All about APOBEC3G

All about APOBEC3G

A gap caused during DNA replication could result in cancer-causing mutations

‘One world, one health’

‘One world, one health’

Minimally invasive method of testing for pathogens could provide new paradigm for characterizing disease transmission

A new biomarker for colon cancer

A new biomarker for colon cancer

CDX2 identifies colon cancer patients who may benefit from chemotherapy

Taking point in point-of-care

Taking point in point-of-care

Abbott to acquire Alere for $5.8 billion and create point-of-care testing leader

Clinical Trials

More than ‘skin-deep’ success

More than ‘skin-deep’ success

Corium posts top-line interim results of transdermal Alzheimer’s patch for once- weekly dosing

Archexin triggers dose-dependent tumor reduction in RCC

Archexin triggers dose-dependent tumor reduction in RCC

Rexahn progresses its Phase 2a clinical research in metastatic renal cell carcinoma

New hope with NEOD001?

New hope with NEOD001?

AL amyloidosis candidate generates favorable cardiac and renal response in Phase 1/2

Getting the body to do the work

Getting the body to do the work

Immune Design shares positive top-line data from trio of Phase 1 trials in immuno- oncology

Research & Development

Finding a better human liver cell

Finding a better human liver cell

Samsara-UC San Diego collaboration to focus on isolating and characterizing specialized human liver cells

A matter of models

A matter of models

Envigo shares findings on the effectiveness of its rat models in examining susceptibility and attenuation to HSV-2 infection

Striking a ‘G’ note on schizophrenia

Striking a ‘G’ note on schizophrenia

Germany’s Boehringer Ingelheim and California’s Arena Pharmaceuticals collaborate in GPCR deal

Johns Hopkins and MedImmune to train Ph.D. students for careers in biopharma

Johns Hopkins and MedImmune to train Ph.D. students for careers in biopharma

The Johns Hopkins University and MedImmune, have announced a first-of-its-kind Ph.D. training program between a major university and a biopharmaceutical company in the United States

Not just basic; translational, too

Not just basic; translational, too

MedImmune and UCSF enter research collaboration aimed at respiratory conditions, inflammation and autoimmunity

Q&A

Q&A: Charles River Laboratories helps navigate the waters of immunotherapy

Q&A: Charles River Laboratories helps navigate the waters of immunotherapy

DDNews speaks with Bill Barbo, senior vice president of global sales and marketing for Charles River Laboratories, about such things as his company’s acquisition of WIL Research and the role Charles River is playing in advancing immunotherapy research

Commentary

Out of order: Clinicians must return to basics

Out of order: Clinicians must return to basics

Medical journals aren't featuring as many basic science articles as they once did, and we should all be worried about that and what it bodes for precision medicine efforts and perhaps drug discovery and development more generally, too.

Guest Commentary: Go parallel in a big way

Guest Commentary: Go parallel in a big way

Production of biotherapeutics can be improved significantly through the use of massively parallel combinatorial screening

Editor's Focus

A cancer cavalcade for March

A cancer cavalcade for March

The annual meeting of the AACR is coming up fast, and that has cancer on our minds and those of a lot of other people, especially drug discovery and development folks. Find out what’s in store for the March issue on the cancer front and some of the activities surrounding oncology right now.

Feature

AACR 2016 Show Preview: The long and winding road

AACR 2016 Show Preview: The long and winding road

Key areas to be addressed at AACR annual meeting include immunotherapy, epigenetics and newer techniques and tools such as CRISPR
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue